Merck & Co., Inc.

MRK
NYSE
Last Updated: 1/23/2022 6:21:40 PM
Price
79.98
Changes
-0.77
% Change
-0.95
Volume
18461735
52 Week
High
91.4
52 Week
Low
68.43511
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck & Co., Inc. Company Details
CEO:   Mr. Kenneth Frazier
Country:   US
Industry:   Drug Manufacturers—General
Website:   https://www.merck.com
Exchange:   New York Stock Exchange
IPO\Launch Date:   1946-06-15
Merck & Co., Inc. Company Executive Details
  Mr. Sanat Chattopadhyay
  Executive Vice President & Pres of Merck Manufacturing Division
  Ms. Jennifer L. Zachary
  Executive Vice President, Gen. Counsel & Corporation Sec.
  Mr. Robert M. Davis
  Pres, Chief Executive Officer & Director
  Mr. Kenneth C. Frazier
  Executive Chairman

Merck & Co., Inc. Latest News

Merck Scores Win In Insurance Battle Over Cyberattack - Bloomberg Report


Bloomberg reported that Merck & Co Inc (NYSE: MRK) has won a long-running legal battle to force its insurer to cover the costs of damages caused by the NotPetya' ransomware' attacks. Merck and its insurers have been battling over $1.4 billion in losses from the attack in 2017 after filing a lawsuit seeking to reclaim financial losses from the "NotPetya" incident.


Published on: 2022-01-21 12:12:42

Impact on Symbol / Company: MRK

View News

Final Trades: Wynn, Goldman Sachs, Merck & more


The "Halftime Report" traders give their top picks to watch for the second half.


Published on: 2022-01-18 13:36:15

Impact on Symbol / Company: MRK

View News

Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022


Merck MRK, +0.07% and partner privately held Ridgeback Biotherapeutics said Tuesday they have won a supply agreement from the United Nations Children's Fund, or Unicef, to provide it with up to 3 million doses of their COVID-19 antiviral molnupiravir in the first half of 2022. The doses will be distributed in more than 100 low and middle-income countries following regulatory authorizations.


Published on: 2022-01-18 06:53:42

Impact on Symbol / Company: MRK

View News

4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes


Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.


Published on: 2022-01-17 10:00:23

Impact on Symbol / Company: MRK

View News

How Do Pfizer's and Merck's COVID Pills Work?


The two oral COVID-19 therapies use completely different mechanisms to fight the coronavirus.


Published on: 2022-01-16 09:31:00

Impact on Symbol / Company: MRK

View News

Week 3 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge


Two sample Breakout Stocks for Week 3 with better than 10% short-term upside potential and a Dow stock pick. This past week was a negative momentum signal and no picks beat 10% peak gains with the picks down -0.08% in total led by TDW +4% and HXL +2.1%.


Published on: 2022-01-15 10:01:46

Impact on Symbol / Company: MRK

View News

2 Top Healthcare Stocks to Buy Right Now


Don't wait too long to buy shares of these two companies.


Published on: 2022-01-14 10:50:00

Impact on Symbol / Company: MRK

View News

Merck Snags Yet Another Indication for This Drug Combo


The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.


Published on: 2022-01-14 06:00:00

Impact on Symbol / Company: MRK

View News

Adding Merck To My High Quality Pharma Holdings


Merck is a large pharmaceutical company with a diversified portfolio of approved medications, and many drugs under clinical trials. Merck's Keytruda is one of the best-selling medications, and an important alternative to chemotherapy for a growing number of cancers.


Published on: 2022-01-13 12:32:39

Impact on Symbol / Company: MRK

View News

IMV Doses First Patient in the Mid-Stage Study With Keytruda


IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda


Published on: 2022-01-13 10:46:24

Impact on Symbol / Company: MRK

View News

Merck (MRK) Stock Sinks As Market Gains: What You Should Know


Merck (MRK) closed the most recent trading day at $81.20, moving -0.58% from the previous trading session.


Published on: 2022-01-12 19:20:48

Impact on Symbol / Company: MRK

View News

Omicron-specific vaccines are ‘already priced into COVID stocks': Jefferies Managing Director


Jefferies Managing Director Michael Yee joins Yahoo Finance Live's Julie Hyman and Brian Sozzi to discuss the biotech sector, outlook for M&A activity, and the outlook for COVID-19 stocks.


Published on: 2022-01-11 12:32:00

Impact on Symbol / Company: MRK

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you